Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare BATS:ADMENYSEAMERICAN:ASTCVE:STA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMEAptus Drawdown Managed Equity ETF$46.52+0.4%$44.19$39.85▼$48.57$236.38M0.7924,457 shs3,726 shsASTAsterias Biotherapeutics$0.00$0.00$0.51▼$2.05$111KN/A136,653 shs1,000 shsSTASanatana ResourcesC$0.67-4.3%C$0.23C$0.08▼C$0.74C$68.23M1.32105,434 shs41,500 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMEAptus Drawdown Managed Equity ETF+0.39%+1.82%+4.85%+1.22%+10.33%ASTAsterias Biotherapeutics0.00%0.00%0.00%0.00%0.00%STASanatana Resources-4.11%+94.44%+536.36%+677.78%+723.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMEAptus Drawdown Managed Equity ETFN/AN/AN/AN/AN/AN/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASTASanatana ResourcesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMEAptus Drawdown Managed Equity ETF 2.71Moderate Buy$46.52N/AASTAsterias Biotherapeutics 0.00N/AN/AN/ASTASanatana Resources 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMEAptus Drawdown Managed Equity ETFN/AN/AN/AN/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/ASTASanatana ResourcesN/AN/AC$0.14 per share4.71C$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMEAptus Drawdown Managed Equity ETFN/AN/A25.45∞N/AN/AN/AN/AN/AASTAsterias BiotherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ASTASanatana Resources-C$2.27M-C$0.01N/A∞N/AN/A-58.40%-54.68%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMEAptus Drawdown Managed Equity ETF$0.210.45%N/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/AN/AN/ASTASanatana ResourcesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMEAptus Drawdown Managed Equity ETFN/AN/AN/AASTAsterias BiotherapeuticsN/AN/AN/ASTASanatana Resources3.475.532.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMEAptus Drawdown Managed Equity ETFN/AASTAsterias BiotherapeuticsN/ASTASanatana ResourcesN/AInsider OwnershipCompanyInsider OwnershipADMEAptus Drawdown Managed Equity ETFN/AASTAsterias BiotherapeuticsN/ASTASanatana Resources10.34%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMEAptus Drawdown Managed Equity ETFN/A5.07 millionN/ANot OptionableASTAsterias BiotherapeuticsN/A55.66 millionN/ANot OptionableSTASanatana Resources3101.84 millionN/ANot OptionableADME, TOM, STA, and AST HeadlinesRecent News About These CompaniesSanatana Resources (CVE:STA) Stock Price Up 46.7% - Should You Buy?June 1 at 1:41 AM | americanbankingnews.comSanatana Resources (CVE:STA) Shares Up 46.7% - Here's What HappenedMay 31 at 10:36 PM | marketbeat.comSanatana Resources (CVE:STA) Stock Price Up 46.7% - Still a Buy?May 31 at 8:45 PM | marketbeat.comSanatana Resources (CVE:STA) Shares Up 46.7% - Should You Buy?May 31 at 7:57 PM | marketbeat.comSanatana Resources (CVE:STA) Shares Up 46.7% - Still a Buy?May 31 at 6:50 PM | marketbeat.comSanatana Resources (CVE:STA) Trading 46.7% Higher - Here's WhyMay 31 at 5:58 PM | marketbeat.comSanatana Resources (CVE:STA) Shares Up 29.1% - Here's WhyMay 31 at 3:53 PM | marketbeat.comSanatana Resources (CVE:STA) Trading 18.2% Higher - Here's WhyMay 31 at 2:47 PM | marketbeat.comSanatana Resources (CVE:STA) Trading 21.8% Higher - Here's WhyMay 31 at 2:09 PM | marketbeat.comSanatana Resources (CVE:STA) Shares Up 20% - Should You Buy?May 31 at 1:12 PM | marketbeat.comSanatana Resources (CVE:STA) Trading 46.7% Higher - Still a Buy?May 31 at 8:54 AM | marketbeat.comSanatana Resources (CVE:STA) Trading 46.7% Higher - Time to Buy?May 31 at 8:11 AM | marketbeat.comSanatana Resources (CVE:STA) Trading 46.7% Higher - Here's What HappenedMay 31 at 8:11 AM | marketbeat.comSanatana Resources (CVE:STA) Shares Up 46.7% - Here's WhyMay 31 at 8:11 AM | marketbeat.comSanatana Resources (CVE:STA) Trading Up 46.7% - Here's What HappenedMay 31 at 7:18 AM | marketbeat.comSanatana Resources (CVE:STA) Trading Up 46.7% - What's Next?May 31 at 5:53 AM | marketbeat.comSanatana Resources (CVE:STA) Trading Up 46.7% - Should You Buy?May 31 at 4:52 AM | marketbeat.comSanatana Resources (CVE:STA) Trading Up 46.7% - Still a Buy?May 31 at 4:52 AM | marketbeat.comSanatana Resources (CVE:STA) Trading 46.7% Higher - Should You Buy?May 31 at 4:31 AM | marketbeat.comSanatana Resources (CVE:STA) Stock Price Up 46.7% - Here's WhyMay 31 at 4:31 AM | marketbeat.comSanatana Resources (CVE:STA) Stock Price Up 46.7% - Here's What HappenedMay 31 at 4:31 AM | marketbeat.comMedia Sentiment Over TimeTop HeadlinesView All HeadlinesQuantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationBy Leo Miller | May 27, 2025View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationHow Does D-Wave Stack Up Against Quantum Competitors?By Nathan Reiff | May 20, 2025View How Does D-Wave Stack Up Against Quantum Competitors?NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?By Leo Miller | May 20, 2025View NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy?Pfizer's 7.5% Dividend: Income Haven or House of Cards?By Jeffrey Neal Johnson | May 23, 2025View Pfizer's 7.5% Dividend: Income Haven or House of Cards?SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the StartBy Thomas Hughes | May 14, 2025View SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the StartADME, TOM, STA, and AST Company DescriptionsAptus Drawdown Managed Equity ETF BATS:ADME$46.52 +0.19 (+0.41%) As of 09:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.The Aptus Drawdown Managed Equity ETF (ADME) is an exchange-traded fund that mostly invests in large cap equity. The fund is actively managed to select large-cap US stocks that exhibit positive fundamental and momentum characteristics combined with a downside hedge. ADME was launched on Jun 8, 2016 and is managed by Aptus.Asterias Biotherapeutics NYSEAMERICAN:AST$0.0020 0.00 (0.00%) As of 07/10/2019Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.Sanatana Resources CVE:STAC$0.67 -0.03 (-4.29%) As of 11:01 AM EasternSanatana Resources Inc., an exploration stage company, engages in the acquisition, exploration, and development of mineral properties. It explores for copper and gold. The company entered in an option agreement to acquire 80% interest in the Oweegee Dome project covering an area of approximately 31,077 hectares located in in Golden Triangle in British Columbia; and 100% interest in the Empress Property, as well as asset purchase agreement to acquire the Santoy Property comprising 32 cell mining claims covering an area of approximately 551 hectares located in in Ontario. It also holds interests in the Fortune Project consisting of 100% interest in the Enid property, which comprises 41 mineral claims in the Timmins, Ontario region. The company was formerly known as Sanatana Diamonds Inc. and changed its name to Sanatana Resources Inc. in April 2011. Sanatana Resources Inc. was incorporated in 2004 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Steel Dynamics Shares Climb After Tariff Announcement Why Super Micro Computer's Upside Could Trigger a Short Squeeze Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Chewy Stock Gets a New $7.1 Billion Investor and Analyst Upgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
